Multiple formulations were evaluated, some of which achieved mean cumulative drug permeation amounts much higher than the existing market leading product.
On a comparative basis, the Alliqua patch exhibited competitive mean cumulative drug permeation with respect to the market leading product for the treatment of pain associated with post-herpetic neuralgia (PHN) or shingles.
The company believes that these results will provide it with options to pursue a 505(b)(2) type of a new drug application (NDA), in addition to a generic route for an abbreviated new drug application (ANDA).
Alliqua intends to proceed to the next stage of its developmental program basis these results.
There are plans to pursue a generic version of an existing pain management patch for the treatment of PHN also.
Alliqua president and director Richard Rosenblum said that Alliqua can become a high quality, low cost producer of this next generation transdermal pain patch, and garner significant market share by utilizing its proprietary hydrogel technology and existing facilities.